http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : S. Avinash Rao (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
Manoj Gupta,Partha Sarathi Choudhury,Sudhir Rawal,Harish Chandra Goel,S. Avinash Rao 대한핵의학회 2018 핵의학 분자영상 Vol.52 No.6
Purpose The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emissiontomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC),andMDAnderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emissiontomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients withbiochemical progression. Methods Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CTwere included. A ≥ 25% increase and ≥2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop wasconsidered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria formolecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD)were calculated. Chi-square test was used for statistical significance. Results Proportion of PD, SD, and PR by RECIST 1.1 and MDA criteria were 44 (50.57%), 39 (44.83%), 4 (4.6%), and 33(39.76%), 48 (57.83%), 2 (2.41%) respectively. Proportion of PD, SD, and PR by PERCIST and EORTC criteria were 71(80.68%), 11 (12.50%), 6 (6.82%), and 74 (84.09%), 8 (9.09%), 6 (6.82%) respectively. Chi-square test showed statisticallysignificant (P < 0.05) higher proportion of progression detected by both molecular criteria as compare to both morphologicalcriteria. Conclusion We concluded that for Ga68-PSMA PET-CT response evaluation, molecular criteria performed better than morphologicalcriteria in mPCa patient with PSA progression.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
